Brainstorm Cell Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chaim Lebovits
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 39.1% |
| CEO tenure | 2yrs |
| CEO ownership | 1.4% |
| Management average tenure | 2yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
May 30Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02BrainStorm Cell Therapeutics EPS beats by $0.07
Apr 26Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
BrainStorm Cell Therapeutics EPS misses by $0.18
Feb 04Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17BrainStorm completes dosing in Phase 2 MS Study
Dec 18BrainStorm launches NurOwn Expanded Access Program
Dec 14What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13BrainStorm's NurOwn flunks in late-stage ALS study
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$442k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$17m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$500k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$1m | US$500k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$500k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$29m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$1m | US$500k | -US$23m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$2m | US$500k | -US$14m |
Compensation vs Market: Chaim's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.
CEO
Chaim Lebovits (53 yo)
2yrs
Tenure
US$1,128,795
Compensation
Mr. Chaim Lebovits is President & Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 2yrs | US$1.13m | 1.42% $ 180.5k | |
| Co-Founder & Independent Vice Chair of the Board | 20.7yrs | no data | 0.18% $ 23.2k | |
| Interim CFO & Controller | 12.1yrs | US$146.78k | 0.076% $ 9.7k | |
| Executive VP | 7.8yrs | US$247.06k | 0.15% $ 18.9k | |
| Executive VP & COO | less than a year | no data | no data | |
| Chief Scientific Advisor | no data | no data | no data | |
| Senior Vice President of Patient Advocacy & Government Affairs | 3yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 1.5yrs | no data | 0.22% $ 28.2k | |
| Senior Vice President of Research and Development | less than a year | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: BCLI's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Vice Chair of the Board | 20.7yrs | no data | 0.18% $ 23.2k | |
| Executive VP | 10.6yrs | US$247.06k | 0.15% $ 18.9k | |
| Independent Chairman of the Board | 4.8yrs | no data | 0.066% $ 8.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Business Advisory Board | 13.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Business Advisory Board | 17.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Director | 6.9yrs | US$12.50k | 0.030% $ 3.9k | |
| Member of Scientific Advisory Board | 2yrs | US$4.46m | no data | |
| Director | less than a year | US$1.01m | 0.42% $ 53.8k | |
| Independent Director | 1.6yrs | no data | no data |
6.9yrs
Average Tenure
64yo
Average Age
Experienced Board: BCLI's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 04:00 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Brainstorm Cell Therapeutics Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ACF Equity Research Limited |
| Jason Kolbert | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |